
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Memorial Sloan Kettering Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration
Absci Teams with Global Cancer Center to Discover Therapeutics Using Generative AI
Details : The collaboration unites Absci’s Generative AI Drug Creation Platform with leading oncology experts to discover and develop up to six novel cancer therapeutics.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 12, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Memorial Sloan Kettering Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
Details : The collaboration combines Absci's Integrated Drug Creation™ platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 04, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Study Phase : Discovery Platform
Sponsor : Almirall
Deal Size : $650.0 million
Deal Type : Partnership
Details : The partnership combines Absci’s de novo AI Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 14, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Discovery Platform
Sponsor : Almirall
Deal Size : $650.0 million
Deal Type : Partnership

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Absci Announces Research Collaboration with Merck
Details : Under the collaboration, Absci will deploy its Bionic Protein™ non-standard amino acid technology to produce enzymes tailored to Merck’s biomanufacturing applications and receive an upfront and certain other milestone payments.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $610.0 million
January 07, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recombinant Human Alpha-Fetoprotein
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Alpha Cancer Technologies
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Alpha Cancer Technologies to License AbSci's SoluPro Strain for the Expression of Alpha-Fetoprotein
Details : Under the terms of the agreement AbSci will prepare the hAFP producing E. coli strain for transfer to Alpha Cancer Technologies' CMO of choice for commercial production.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
July 22, 2020
Lead Product(s) : Recombinant Human Alpha-Fetoprotein
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Alpha Cancer Technologies
Deal Size : Undisclosed
Deal Type : Licensing Agreement

 Reset All
Reset All